SHANGHAI, BUDAPEST, Hungary and LONDON, Sept. 6, 2016 /PRNewswire/ -- Shanghai Newsummit Biopharma Group Co. Ltd and Indiso Ltd, a company specializing in treatments for unmet medical needs of pulmonary and chronic respiratory diseases announced today the signing of a collaboration agreement to design and carry out clinician trials in China utilizing Indiso's proprietary technology and treatment to deliver relief from chronic respiratory syndromes. The signing took place at the Wenzhou Biomedical Innovation Center Healthcare Forum held during the week of the China G20 Summit in the presence of Mr. Dai Tao, Deputy Director of the Development Center for Medical Science & Technology of the National Health & Family Planning Commission, and Mr. Zhang Geng, Mayor of Wenzhou.
Respiratory diseases and allergies are significant and increasing healthcare problems both in China and the rest of the world. It is also understood that the increase in respiratory and allergic syndromes is also connected to climate change and industrial and environmental pollutions. China President Xi Jinping ratified the Climate Change Treaty at the G20 in Hanzhou, and in parallel healthcare related organizations are moving to provide solutions for these conditions.
Under the terms of the agreement, test sites will be established in leading Chinese hospitals to carry out clinical research using the Indiso Speleo Therapy. This China based trial program will be an expansion of the further clinician and patient trials that Indiso will be undertaking in UK NHS hospitals and other EU hospitals.
Dr. Ren Jun, CEO of Shanghai Newsummit Biopharma Group said: "We are very excited to trial the Indiso Speleo Therapy which through its natural product treatment has the capability to provide China-relevant solutions to respiratory conditions prevalent in all healthcare systems as well as offering potentially wider environmental applications."
Dr. Laszlo Urge, Board member at Indiso and at DBH Investment, the venture capital investor in Indiso, added: "We are very encouraged by this partnership. Newsummit is a professional organization with a proven track record of bringing healthcare innovation and solutions into practice and the Indiso Speleo Therapy will now be delivered for the greater benefit of Chinese patients. Importantly, the Indiso treatment can also generate substantial savings to healthcare administrations by reducing the need for in-hospital intensive care treatment and ultimately offering patient home care for respiratory conditions."
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shanghai-newsummit-biopharma-group-and-indiso-sign-collaboration-agreement-for-clinician-trials-and-commercial-development-in-china-300322750.html
SOURCE DBH Investment; Indiso Ltd